United States newsroom

MELVILLE, N.Y., Sep 17, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" in OSI's reissue...

DEERFIELD, IL, September 15, 2009 – Astellas Pharma US, Inc. today announced the winners of the Astellas Ride of a LifetimeSM 2010 contest. The contest asked transplant recipients to submit...

Chicago Mayor Richard M. Daley honored Astellas Pharma US, Inc. and two other Chicagoland companies on Aug. 14 at a ceremony in downtown Chicago with an award for their exemplary learning and...

Astellas Pharma US, Inc. ("Astellas") announced today an update regarding the status of the request for emergency relief and preliminary injunction from the U.S. Food and Drug Administration's...

In a ceremony recognizing "Chicago's 101 Best and Brightest Companies to Work For," Astellas Pharma US, Inc. won an Elite award for employee engagement and commitment by the National Association...

Unique needs of transplant patients require special care to preserve their gift of life Astellas Pharma US, Inc. ("Astellas") announced today that the U.S. Food and Drug Administration (FDA) has...

Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache SAN DIEGO, CA, and DEERFIELD, IL (August 3, 2009): Zogenix, Inc. (“Zogenix”), a privately held...

MELVILLE, N.Y., Aug 01, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib)...

MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jul 13, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. today announced that SATURN, a pivotal Phase III study of...

MELVILLE, N.Y.--(BUSINESS WIRE)--July 6, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...

MELVILLE, N.Y., Jun 15, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...

DEERFIELD, IL, June 4, 2009 – Astellas Pharma Global Development (“APGD”), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Betsy Garofalo has been hired...

DEERFIELD, IL, June 1, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Dan Dunham as the vice president of compliance. Dunham will be responsible for governance of the compliance...

Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy ORLANDO, Fla., May 30, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that...

Deerfield, IL (May 28, 2009) – The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf® (tacrolimus) in conjunction with mycophenolate...

DEERFIELD, IL, May 28, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Walt Johnston as vice president of marketing. Reporting directly to Patrick Shea, senior vice president of...

Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma Patients with an EGFR Mutation Achieved a 10 Fold Increase in the Time Patients Live...

Arginine vasopressin (AVP) receptor antagonist now available in new premixed formulation DEERFIELD, Illinois, April 1, 2009 — Astellas Pharma US, Inc. today announced the commercial availability...

Company continues path toward goal to become global category leader DEERFIELD, IL, April 1, 2009 – Astellas Pharma US, Inc. (“Astellas”) announced today Seigo Kashii, has been appointed...

Roche Submits Marketing Authorization Application for Approval of Tarceva as a First-line Maintenance Therapy in Europe MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar. 19,...

MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 10, 2009-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals...

Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy MELVILLE, N.Y.--(BUSINESS WIRE)-- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that its U.S....

MELVILLE, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) welcomes today's announcement by the U.K.'s National Institute for Health and Clinical Excellence (NICE)...

First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment SOUTH SAN FRANCISCO, Calif. & MELVILLE,...

Arginine vasopressin (AVP) receptor antagonist now approved in single-use premixed formulation DEERFIELD, Illinois, October 22, 2008 — Astellas Pharma US, Inc. today announced that the U.S. Food...

DEERFIELD, IL, October 14, 2008 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the fourth annual Astellas Ride of a Lifetime contest. Launched...

SOUTH SAN FRANCISCO, Calif. & MELVILLE, N.Y.-- Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin®

Greater Chicago-area science teachers gain resources to inspire young scientists in the classroom DEERFIELD, IL, October 1, 2008 – Astellas Pharma US, Inc. (“Astellas”) is pleased to...

Vancouver, Canada and Deerfield, Illinois, USA, August 11, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...

First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease Deerfield, Ill., June 24, 2008 – Astellas Pharma US, Inc. today announced the commercial availability...

First A2A Adenosine Receptor Agonist Approved for Use as Pharmacologic Stress Agent in Myocardial Perfusion Imaging PALO ALTO, Calif. and DEERFIELD, Ill., April 10 /PRNewswire-FirstCall/ -- CV...

Deerfield, Illinois and Vancouver, Canada, March 25, 2008 -- Astellas Pharma US, Inc. and its co-development partner Cardiome Pharma Corp. announced the first pivotal Phase III study evaluating...

MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 27, 2008--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it has filed with the U.S. Patent and Trademark Office an application to reissue its...

PRNewswire DEERFIELD, Ill. Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved their Supplemental New Drug Application (sNDA) seeking approval for...

Vancouver, Canada and Deerfield, Illinois, USA, January 21, 2008 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...

MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 14, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Tarceva® (erlotinib) has been listed on Japan's National Health Insurance (NHI) drug...

Vancouver, Canada and Deerfield, Illinois, USA, December 11, 2007 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. (“Astellas”) today...

ORLANDO, FL – November 7, 2007 – Astellas Pharma US, Inc. today announced that the investigational agent vernakalant hydrochloride increased conversion to normal heart rhythm (sinus rhythm, or...

Deerfield, Illinois – October 25, 2007 – Astellas Pharma US, Inc. today announced data demonstrating that VAPRISOL® (conivaptan hydrochloride injection) effectively raises serum sodium...

BASEL, Switzerland & MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 22, 2007--Roche and OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that Tarceva® (erlotinib) has been approved in Japan for...

SOUTH SAN FRANCISCO, CA and DEERFIELD, IL/OCTOBER 22, 2007 – Theravance, Inc. (NASDAQ: THRX) and Astellas Pharma US, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued...

Educational program offers unique resources to empower transplant patients and their caregivers DEERFIELD, IL, October 17, 2007 – Astellas Pharma US, Inc., a leader in the field of...

Reaffirms 2007 Global Tarceva Sales Guidance MELVILLE, N.Y.--(BUSINESS WIRE)--Oct. 15, 2007--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) provided commentary today on third quarter U.S. Tarceva sales....

DEERFIELD, IL, October 11, 2007 – Astellas Pharma US, Inc., a leader in the field of transplantation, has announced the winners of the third annual Astellas Ride of a Lifetime contest. Launched...

MELVILLE, N.Y.--(BUSINESS WIRE)--Sept. 18, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that the Company has received Notice of Final Determination from the US Patent and...

MELVILLE, N.Y., Sep 07, 2007 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of selected data from over 58 studies involving the Company's lead product,...

CHICAGO--(BUSINESS WIRE)--June 5, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) today provided a summary of studies highlighting data involving the Company's lead product, Tarceva®, presented...

MELVILLE, N.Y.--(BUSINESS WIRE)--April 25, 2007--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that results published yesterday in the Journal of Clinical Oncology show that adding...

Arginine vasopressin (AVP) receptor antagonist now approved for the management of the two most common forms of potentially life-threatening sodium/water imbalance DEERFIELD, Illinois, March 2,...

Multi-award winning program offers resources to empower transplant patients and their caregivers DEERFIELD, IL, February 26, 2007 – Astellas Pharma US, Inc., a leader in the field of...